National Heart, Lung, and Blood Institute Twin Study
|First Received Date ICMJE||May 25, 2000|
|Last Updated Date||March 15, 2016|
|Start Date ICMJE||July 1969|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE||Not Provided|
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT00005124 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||National Heart, Lung, and Blood Institute Twin Study|
|Official Title ICMJE||Not Provided|
|Brief Summary||To assess genetic effects on the variation of cardiovascular and pulmonary risk factors in a cohort of 514 pairs of white male veteran twins.|
In 1966, the National Academy of Sciences-National Research Council (NAS-NRC) began the development of a twin registry. Through state birth records, a group of twins born in 1917-1927 was ascertained and matched to veteran records to obtain a roster of 16,000 twins where both members of the pair were in military service. Veterans formed the basis of the registry because Veterans Administration files provided access to current addresses as well as potential for mortality follow-up. From this roster, a group of twins living within 200 miles of the examining centers and agreeing to cooperate was examined. This procedure yielded a set of 514 pairs of twins where both members of the pair were examined. At the time of initial examination, the World War II veteran twins were 42-56 years old. Since the initial examination, the twins have been followed by the NAS-NRC to maintain current addresses and mortality information.
The World War II veteran cohort was originally examined during the 1969-1973 period at five examination centers located in Framingham, Massachusetts; Davis, San Francisco, Los Angeles, California; and Indianapolis, Indiana. The objective of the initial examination was to estimate the heritability of cardiovascular risk factors. Results of the first examination showed significant heritability for height, weight, relative weight, systolic and diastolic blood pressure, glucose tolerance, uric acid, hematocrit, plasma triglycerides, and forced expiratory volume but not for total plasma cholesterol or any of the lipoprotein cholesterol fractions
.A second exam of the cohort was completed during 1981-1982. Of the original cohort of 1028 subjects, 792 or 77 percent were reexamined and approximately 5.5% had died. The objective of the second examination was to assess the change in cardiovascular risk factors over the ten year interval, assess the disease experience of the cohort and gather additional data on new cardiovascular risk factors as well as pulmonary function measurements and covariates. Examination two differed from examination one in that there was greater opportunity to standardize data collection for methods, laboratories, equipment, and time of examination. Greater emphasis was placed on pulmonary function testing. One objective of examination two that was not achieved was the determination of a sufficient number of cardiovascular events to do analyses of concordance of disease and analyses of disease occurrence in relation to risk factors. Analysis of data on 167 monozygotic pairs of twins and 176 dizygotic pairs of twins showed results similar to those of the first examination for systolic and diastolic blood pressure but, unlike the first examination, also showed significant genetic variance for total cholesterol and LDL cholesterol. HDL cholesterol continued to show no genetic variance.
The third examination of the original cohort was conducted in 1986-1987. The primary objective of the third examination was to assess the incidence of cardiovascular and pulmonary diseases for analyses relative to risk factor data and determine if the heritability of cardiovascular disease exceeded what was expected based on the known cardiovascular risk factors. Extensive pulmonary function testing was part of examination three as it was for examination two and provided longitudinal data for analyses of change in pulmonary function in relation to genetic and environmental factors. The exercise electrocardiogram was expanded to the entire cohort for examination three to provide additional data on sub-clinical disease.
The study was longitudinal in design and consisted of three examinations of the cohort over a period of eighteen years. Data collected in examination one in 1969-1973 included: a twin history questionnaire; personal, family and medical histories; a diet history; a physical examination; numerical data on anthropometry, hematology, and pulmonary function; supplemental lab data; an X-ray; clinical diagnostic impression; electrocardiogram; and blood analysis-fasting lipids. Data collected in examination two in 1981-1982 included: a personal and family history; deceased twin information; residence and occupational history; Thurstone Activity Scale; leisure time physical activity; social support; medical history; physical examination; clinical diagnostic impression; job mobility and stress; retirement information; Jenkins Activity Survey; blood lipid measurements. Data collected in examination three in 1986-1987 included the same data as collected in examination two plus an assessment of the prevalence for all twins and the incidence for a subgroup of twins of preclinical cardiovascular disease detected through noninvasive techniques.
The follow-up exam in 1986-87 collected baseline data on cognitive performance in 622 individuals, including 132 monozygotic and 134 dizygotic twin pairs. Beginning in December, 1994, a research grant was used to conduct a fourth exam in the surviving subjects of this cohort that used this rich resource of available data to determine the relationship between cardiovascular risk factors collected over 23 years of follow-up, changes in cognitive function since the last exam, and brain morphology assessed by magnetic resonance imaging (MRI). Given the mean age of this cohort (72 years) in 1995, the next several years represented a critical time to monitor age related changes in brain morphology and cognition. The addition of a fourth exam made the NHLBI Twin Study the longest longitudinal study of cardiovascular disease epidemiology in twin subjects (23 to 25 years of follow-up) and the first to investigate the contribution of genes and the environment to associations between CVD risk factors, cognitive performance, and brain morphology. There were five specific objectives of this study. The first was to evaluate the prospective and cross-sectional relationships of cardiovascular risk factors collected over 23 years of follow-up (e.g., blood pressure, lipids, obesity, smoking) and indices of brain morphology assessed at the fourth exam. The second objective was to determine the extent that twins discordant for essential hypertension or non-insulin-dependent diabetes mellitus (NIDDM) or cardiovascular disease (CHD) showed different MRI profiles. The third was to characterize the neuropsychological changes in performance from Exam 3 to Exam 4 and determine the contribution of genes and the environment to stability or change. The fourth objective was to use the data from exams 1 to 3 to investigate prospective relationships between CVD risk factors and decline in cognitive performance from Exam 3 to Exam 4. The fifth was to determine the heritability of the new measurements obtained for the first time at the fourth examination cycle (e.g., MRI measures of infarct area and localization, white matter hyperintensities (WMHI), and ventricular volumes).
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
|Study Type ICMJE||Observational|
|Study Design ICMJE||Not Provided|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Intervention ICMJE||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Enrollment ICMJE||Not Provided|
|Completion Date||November 1998|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||No eligibility criteria|
|Ages||up to 100 Years (Child, Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Not Provided|
|Removed Location Countries|
|NCT Number ICMJE||NCT00005124|
|Other Study ID Numbers ICMJE||903
R01HL051429 ( US NIH Grant/Contract Award Number )
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||National Heart, Lung, and Blood Institute (NHLBI)|
|Collaborators ICMJE||Not Provided|
|Information Provided By||National Heart, Lung, and Blood Institute (NHLBI)|
|Verification Date||May 2000|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP